Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals, retaining the price target of $4.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Actinium Pharmaceuticals’ promising pipeline and financial health. The company reported better-than-expected financial results for the second quarter of 2025, with an EPS that surpassed both the firm’s and consensus estimates. Actinium’s strong cash position, with approximately $59.9 million, is expected to support operations through 2028, providing a solid financial foundation for ongoing and future projects.
Actinium’s pipeline is robust, with multiple trials underway that could drive significant value. The company is advancing several key studies, including a Phase 2/3 trial of Actimab-A in combination with CLAG-M for AML, and exploring Actimab-A with Keytruda or Opdivo for certain cancer types. Additionally, the initiation of a Phase 1b/2 trial for Iomab-ACT in CAR-T therapy and the agreement with the FDA on the Iomab-B trial protocol further strengthen the company’s prospects. These developments, along with strategic efforts to seek partnerships, underpin Pantginis’s optimistic outlook on Actinium’s stock.